Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Cash from Operations (2016 - 2025)

Lisata Therapeutics' Cash from Operations history spans 13 years, with the latest figure at 3249000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 28.25% year-over-year to 3249000.0; the TTM value through Dec 2025 reached 15949000.0, up 17.6%, while the annual FY2025 figure was 15949000.0, 17.6% up from the prior year.
  • Cash from Operations reached 3249000.0 in Q4 2025 per LSTA's latest filing, up from 3342000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 2518000.0 in Q3 2024 to a low of 8196000.0 in Q1 2023.
  • Average Cash from Operations over 3 years is 4611416.67, with a median of 4126500.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: increased 29.72% in 2024, then crashed 32.72% in 2025.
  • A 3-year view of Cash from Operations shows it stood at 4069000.0 in 2023, then decreased by 11.28% to 4528000.0 in 2024, then grew by 28.25% to 3249000.0 in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Cash from Operations are 3249000.0 (Q4 2025), 3342000.0 (Q3 2025), and 3956000.0 (Q2 2025).